27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
Viracta Therapeutics Inc (NASDAQ:VIRX) announced that the relapsed or refractory EBV+ peripheral T-cell lymphoma (R/R EBV+ PTCL) cohort of their pivotal NAVAL-1 clinical trial met the pre-specified efficacy threshold for advancement to Stage 2 of the study.
The decision to expand NAVAL-1 cohorts from Stage 1 to Stage 2 is based on achieving a predetermined minimum number of objective responses within the first ten enrolled patients.
Mark Rothera, President & CEO, says, "Initial data from the PTCL cohort in NAVAL-1 show a strong signal of efficacy that is in-line with our promising Phase 1b/2 data and sufficient to advance to Stage 2. We now look forward to completing enrollment in Stage 1 and are taking steps to further accelerate enrollment through Stage 2."
Enrollment for NAVAL-1 is ongoing worldwide, and updates regarding potential advancements in additional cohorts are anticipated in the latter half of 2023.
As of March 31, 2023, the company had a cash balance of $80.3 million, providing an anticipated cash runway into late 2024.
Price Action: VIRX shares are up 5.5% at $1.51 on the last check Wednesday.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!